DaVita (DVA) Q2 2026 earnings review
Margin Expansion and Market Share Grabs Eclipse Revenue Per Treatment Squeeze
DaVita delivered a highly profitable Q2, featuring a 36% YoY surge in adjusted EPS to $4.02 on a 5.1% revenue increase. The long-awaited reversal in treatment volumes finally materialized (+0.3% YoY normalized), largely fueled by aggressive market share capture from competitor clinic closures (Fresenius). Operating margins accelerated to 16.3%, up from 14.1% in the prior quarter, driven by strong labor productivity that offset sequential declines in Revenue Per Treatment. With $348 million in buybacks retiring another 2.2 million shares, DaVita's capital return engine continues to mathematically juice the bottom line, allowing management to confidently reiterate their robust FY26 guidance.
🐂 Bull Case
After years of post-COVID mortality headwinds and missed treatments, U.S. normalized non-acquired treatment growth flipped positive to +0.3% YoY. DaVita is successfully capitalizing on competitor weakness to fill chairs.
DaVita repurchased 2.2 million shares for $348M in Q2, and another 200K shares post-quarter. This aggressive float reduction mathematically guarantees outsized EPS growth relative to core net income.
🐻 Bear Case
RPT declined sequentially from $417.59 to $415.87. As the ACA commercial mix shifts toward lower-paying Bronze plans, DaVita risks losing pricing leverage against sticky long-term cost inflation.
The Integrated Kidney Care (IKC) segment swung violently from a $19M loss in Q1 to a $40M profit in Q2. Such massive intra-year swings make modeling future cash flows highly unpredictable.
⚖️ Verdict: 🟢
Bullish. DaVita is controlling what it can: scooping up competitor market share, managing labor efficiency tightly, and using free cash flow to decimate the share count. The EPS and OI beats are high quality.
Key Themes
Competitor Missteps Gift Market Share
DaVita's U.S. normalized treatment growth of +0.3% YoY represents a critical reversing trend from the negative prints of 2024 and 2025. This volume growth is not a structural macro expansion of the ESRD market, but rather a direct benefit of competitor (Fresenius) clinic closures. By absorbing these orphaned patients, DaVita is leveraging its fixed-cost clinic footprint to drive incremental, high-margin volume.
Labor Productivity Crushes Care Costs
Accelerating labor efficiencies drove Patient Care Costs (PCC) per treatment down to $277.40 from $280.11 sequentially. This structural improvement in training retention and staffing models effectively offset the sequential top-line pressure in revenue per treatment, shielding the gross margin profile.
Revenue Per Treatment (RPT) Squeeze
Despite the positive narrative surrounding volume, pricing power is decelerating. Average patient service revenue per treatment dropped sequentially by $1.72 (to $415.87). Management had previously warned of a 'modest RPT headwind' as commercial ACA patients migrate toward higher-deductible Bronze plans. This specific data point directly contradicts the otherwise flawless operational beat and requires close monitoring into H2.
Tech Ambitions Bloat G&A
General and Administrative expenses per treatment rose to $45.79 (up from $43.43 in 25Q2). The company continues to plow heavy investments into 'Schedule Hub' and modernizing data infrastructure under the banner of AI. While pitched as a long-term efficiency play, the immediate reality is accelerating corporate overhead that outpaces top-line revenue growth.
IKC's Wild Ride Lands on Profitability
The value-based care segment (Integrated Kidney Care) delivered a massive reversing trend, generating $40M in operating income after a $19M loss in Q1. While incredibly lumpy due to the timing of shared savings recognition in the CMS CKCC program, this print validates the underlying economics of their hands-on clinical model.
International Operations Decelerating
While domestic operations shined, the International segment operating income decelerated sharply to $25M from $36M a year ago, despite an increase in top-line revenue. This margin compression overseas acts as a minor, yet persistent, drag on the enterprise.
Other KPIs
Accelerating massively from $157M in 25Q2. The LTM Free Cash Flow now sits at an impressive $1.308 billion, which comfortably funds the company's voracious appetite for its own stock ($348M repurchased in the quarter).
Stable and compounding. This segment acts as the bedrock of DaVita's cash generation, successfully shrugging off sequential pricing declines through strict operational cost management.
Guidance
Stable. Management maintained the raised guidance from Q1. This implies a highly controlled H2, expecting sustained labor efficiencies and continued integration of new patient volumes to offset any further commercial mix deterioration.
Stable. The midpoint of $14.65 implies a massive ~36% acceleration over FY25's $10.78. This is virtually locked in due to the heavy reduction in outstanding shares; the buyback math is doing the heavy lifting here.
Stable. Reaffirmed range. With $396M generated in H1, DaVita historically experiences back-half weighted cash flows due to working capital dynamics, making this target highly achievable.
Key Questions
Commercial Mix Degradation
RPT declined sequentially despite positive volume growth. To what extent is the shift towards lower-tier ACA Bronze plans permanently resetting your baseline pricing expectations for 2027?
Market Share Stickiness
You've successfully capitalized on Fresenius clinic closures to flip volume growth positive. Once this competitive retrenchment concludes, what organic levers do you have to maintain positive treatment growth?
IKC Volatility
IKC swung from a $19M loss to a $40M profit in a single quarter. Can we expect smoothing of shared savings recognition going forward, or will this segment remain perpetually volatile on a quarterly basis?
Technology ROI
G&A costs continue to outpace top-line growth to fund AI and Schedule Hub rollouts. When will these specific technology investments crossover from being a G&A drag to providing visible, bottom-line operating leverage?